BMEZ (BlackRock Health Sciences Trust II) Risk Assessment

View and export this data going back to 1990. Start your Free Trial

What is BlackRock Health Sciences Trust II Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BlackRock Health Sciences Trust II is: No Data: Cannot be evaluated.

Competitive Comparison of BlackRock Health Sciences Trust II's Risk Assessment

For the Asset Management subindustry, BlackRock Health Sciences Trust II's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BlackRock Health Sciences Trust II's Risk Assessment Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BlackRock Health Sciences Trust II's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BlackRock Health Sciences Trust II's Risk Assessment falls into.

BlackRock Health Sciences Trust II (NYSE:BMEZ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BlackRock Health Sciences Trust II Risk Assessment Related Terms

Thank you for viewing the detailed overview of BlackRock Health Sciences Trust II's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BlackRock Health Sciences Trust II Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BlackRock Health Sciences Trust II (NYSE:BMEZ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Bellevue Parkway, Wilmington, DE, USA, 19809

Website

https://www.blackrock.com

BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Christopher Accettella	other: Portfolio Manager	100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Kyle Mcclements	other: Portfolio Manager	100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Arthur Philip Steinmetz	director	50 HUDSON YARDS, NEW YORK NY 10001
Aaron David Wasserman	officer: Chief Compliance Officer	50 HUDSON YARDS, NEW YORK NY 10001
Lorenzo Flores	director	2100 LOGIC DRIVE, SAN JOSE CA 95124
James Phillip Holloman	director	P.O. BOX 625737, 6800 CINTAS BOULEVARD, CINCINNATI OH 45262
Stayce D. Harris	director	1999 S. BASCOM AVE., SUITE 700, CAMPBELL CA 95008
Trent Walker	officer: Chief Financial Officer	C/O PIMCO, 650 NEWPORT CENTER DRIVE, NEWPORT BEACH CA 92660
Xiang Liu	other: Portfolio Manager	55 EAST 52ND STREET, NEW YORK NY 10055
Jeffrey Gene Lee	other: Portfolio Manager	55 EAST 52ND STREET, NEW YORK NY 10055
Blackrock Financial Management Inc/de	other: Affil. of Investment Adviser	100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Robert Glenn Hubbard	director	100 BELLEVUE PARKWAY, WILMINGTON DE 19809
Robert W Fairbairn	director	55 EAST 52ND STREET, NEW YORK NY 10055